Sobi to present new data across its haematology portfolio at the 2024 EHA congress
Sobi® will present data at the EHA (European Haematology Association) hybrid congress, taking place in Madrid on the 13-16th June, highlighting the company’s dedication to advancing treatments for rare and debilitating haematological diseases. The congress will feature Sobi's latest advances in the treatment of immune thrombocytopenia (ITP), myelofibrosis, haemophilia A, and paroxysmal nocturnal haemoglobinuria (PNH). “We look forward to sharing new data related to several of Sobi’s therapeutic areas at this year’s EHA congress,” said Lydia Abad-Franch, MD, Head of R&D and Medical